Haematopoietic system

Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

Retrieved on: 
Thursday, September 12, 2024
Acute myeloid leukemia, Fungal infection, Intensive care medicine, ITT, Haematopoietic system, Cohort, Bloodstream infections, Blood, Patient, Therapy, Safety, Prevalence, FDA, Arm, Disease, Chronic liver disease, ID, Conference, Cancer, Cis, HSCT, David Berry (inventor), Food, Febrile neutropenia, Breakthrough therapy, Death, Gastrointestinal tract, Interval (mathematics), Literature, CMC, Acute leukemia, Mortality, Myelodysplastic syndrome, Risk, Odds ratio, Incidence, Infection, GI, Conference call, Bacteria, Graft-versus-host disease

ET today

Key Points: 
  • ET today
    CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today reports topline clinical data from Cohort 2 of its SER-155 Phase 1b placebo-controlled study in patients undergoing allo-HSCT.
  • SER-155 is an investigational live oral biotherapeutic cultivated from clonal master cell banks designed to prevent GI-derived bacterial bloodstream infections and other pathogen-associated complications.
  • The Company also intends to evaluate SER-155 in additional patient populations that have a high risk of serious bacterial infections.
  • “Given our encouraging clinical results and the severe consequences of bacterial infections, we will pursue Breakthrough Therapy designation with the FDA.

September 2024 Letter to Shareholders

Retrieved on: 
Monday, September 9, 2024
TNBC, COVID-19, Haematopoietic system, Clinical, MASH, Trial of the century, Annual report, AmfAR, Colorectal cancer, Clinical Therapeutics, University, Inflammation, Research, FDA, Chronic fatigue syndrome, Syneos Health, Triple-negative breast cancer, HIV, LATCH, Regenerative medicine, AIDS, Partnership, Manuscript, Biomarker, CD10, Letter, Patient, CCR5, Mouse, B cell, CRC, Clinical trial, HIV/AIDS research, MD Anderson Cancer Center, Pharmaceutical industry

As we enter the final stretch of 2024, let me first acknowledge that there is still a great deal of work ahead of us.

Key Points: 
  • As we enter the final stretch of 2024, let me first acknowledge that there is still a great deal of work ahead of us.
  • We are committed to being transparent with our shareholders and it is my pleasure to provide an update on some key developments described below.
  • As shareholders, you remain the lifeblood of the Company, and we remain committed to acting in your best interests.
  • Our commitment is to drive value for you – the shareholders – and to bring better healthcare to patients in need.

City of Hope Appoints Simon Nazarian as Chief Digital and Technology Officer to Drive Innovation and Digital Transformation

Retrieved on: 
Tuesday, September 3, 2024
Hospitals, Health, Oncology, AI, NCI, Sony Pictures, News, BMT, Research, McKinsey & Company, City, Multimedia, Optum, Haematopoietic system, Cancer, Kaiser Permanente, Overalls, Digital, Rock (geology), San Diego State University, Bone marrow, Patient, National Cancer Institute

In this role, Nazarian will lead City of Hope’s overall technology strategy, transforming and expanding technology innovation through digital, AI and advanced analytics initiatives.

Key Points: 
  • In this role, Nazarian will lead City of Hope’s overall technology strategy, transforming and expanding technology innovation through digital, AI and advanced analytics initiatives.
  • Nazarian will report to Robert Stone, City of Hope’s chief executive officer.
  • “I’m so pleased to welcome Simon to City of Hope to propel our mission forward.
  • “I am truly honored to join City of Hope, an organization that is renowned for its cancer research, treatment and innovation," Nazarian said.

Human medicines European public assessment report (EPAR): Accofil, filgrastim, Date of authorisation: 17/09/2014, Revision: 17, Status: Authorised

Retrieved on: 
Friday, August 30, 2024
European Commission, Patient, INN, DSM-IV codes, Leukemia, IIA, HIV/AIDS, Commission, ANC, Language, Marketing, Breast cancer, Pain, Syndrome, History, Febrile neutropenia, ATC, Medicine, European, Fever, Risk, Literature, Skin, HIV, Medical Subject Headings, Anatomy, Agency, Infection, Syringe, DNA, Cancer, Cell, Bone marrow, Select, Female, Malignancy, Acute leukemia, CHMP, Bacteria, Neutrophil, Risk management, Incidence, Haematopoietic system, Overview, Safety, International, Medical device

Human medicines European public assessment report (EPAR): Accofil, filgrastim, Date of authorisation: 17/09/2014, Revision: 17, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Accofil, filgrastim, Date of authorisation: 17/09/2014, Revision: 17, Status: Authorised

Bone Harvester Market to Reach $23.4 Million, Globally, by 2033 at 5.7% CAGR: Allied Market Research

Retrieved on: 
Tuesday, August 27, 2024
Spinal stenosis, Haematopoietic system, Hospital, Growth, Degenerative disc disease, Prevalence, Bone fracture, Bone marrow

According to the report, the bone harvester market was valued at $13.5 million in 2023, and is projected to reach $23.4 million by 2033, growing at a CAGR of 5.7% from 2024 to 2033.

Key Points: 
  • According to the report, the bone harvester market was valued at $13.5 million in 2023, and is projected to reach $23.4 million by 2033, growing at a CAGR of 5.7% from 2024 to 2033.
  • The global bone harvester market is experiencing growth due to surge in geriatric population, high adoption of bone marrow transplantation, and rise in prevalence of orthopedic disorders.
  • The bone harvester market is segmented into type, application, end user, and region.
  • On the basis of type, the market is divided into marrow harvesting and cancellous bone harvesting.

Bone Harvester Market to Reach $23.4 Million, Globally, by 2033 at 5.7% CAGR: Allied Market Research

Retrieved on: 
Tuesday, August 27, 2024
Spinal stenosis, Haematopoietic system, Hospital, Growth, Degenerative disc disease, Prevalence, Bone fracture, Bone marrow

According to the report, the bone harvester market was valued at $13.5 million in 2023, and is projected to reach $23.4 million by 2033, growing at a CAGR of 5.7% from 2024 to 2033.

Key Points: 
  • According to the report, the bone harvester market was valued at $13.5 million in 2023, and is projected to reach $23.4 million by 2033, growing at a CAGR of 5.7% from 2024 to 2033.
  • The global bone harvester market is experiencing growth due to surge in geriatric population, high adoption of bone marrow transplantation, and rise in prevalence of orthopedic disorders.
  • The bone harvester market is segmented into type, application, end user, and region.
  • On the basis of type, the market is divided into marrow harvesting and cancellous bone harvesting.

Vertex Announces CASGEVY™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in England

Retrieved on: 
Thursday, August 8, 2024
Health, Hospitals, Stem Cells, Genetics, Pharmaceutical, Biotechnology, Haematopoietic system, Hemoglobinopathy, Medication, Senior, Kingdom, Vertex Pharmaceuticals, TDT, SCD, NHS, MHRA, Hospital, Patient, Sickle cell disease, European, NHS England, VRTX, Health care, CRISPR, Vertex, Pharmaceutical industry

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible transfusion-dependent beta thalassemia (TDT) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY™ (exagamglogene autotemcel), from today.

Key Points: 
  • Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible transfusion-dependent beta thalassemia (TDT) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY™ (exagamglogene autotemcel), from today.
  • The reimbursement agreement comes as the National Institute for Health and Care Excellence (NICE) issues positive guidance recommending CASGEVY’s use in the NHS.
  • “Securing access to CASGEVY is a historic moment for people living with transfusion-dependent beta thalassemia who, for too long, have had limited options for this life-shortening disease,” said Ludovic Fenaux, Senior Vice President, Vertex International.
  • Vertex continues to work collaboratively with NICE and NHS England to ensure eligible sickle cell disease (SCD) patients in England can also access this treatment as soon as possible.

16th Annual Ride for SickKids takes place August 11, 2024

Retrieved on: 
Wednesday, August 7, 2024
Haematopoietic system, Police, Leg, Insurance, Health, Child, Hope, Survival, Hospital for Sick Children, Lunch, Ride, General insurance, Cancer, Family, GTA, Entertainment

TORONTO, Aug. 7, 2024 /CNW/ - More than 600 motorcycle riders who are passionate about supporting children's health are gearing up for the 16th Annual Ride for SickKids fundraiser, a 150 km journey through York Region.

Key Points: 
  • TORONTO, Aug. 7, 2024 /CNW/ - More than 600 motorcycle riders who are passionate about supporting children's health are gearing up for the 16th Annual Ride for SickKids fundraiser, a 150 km journey through York Region.
  • One of the largest annual rides in the GTA, the Ride for SickKids has raised $1.2 million for the SickKids Foundation since it began in 2009.
  • The Ride for SickKids will begin and end at the North Maple Regional Park in Vaughan.
  • Every year, Ride for SickKids features a special guest – a courageous patient from the hospital – to share their powerful story with our participants.

City of Hope and Institute for Follicular Lymphoma Innovation (IFLI) Announce $2 Million Research Program in Follicular Lymphoma

Retrieved on: 
Tuesday, July 30, 2024
Oncology, Health, Diabetes, Hospitals, Research, Science, Pharmaceutical, City, Hematology, Multimedia, Frustration, Patient, Malignancy, Tumor microenvironment, Haematopoietic system, Beckman Research Institute, Follicular lymphoma, Medical device

City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States, and Institute for Follicular Lymphoma Innovation (IFLI) today announced a $2 million, three-year collaboration to study spontaneous remission in follicular lymphoma, the most common, slow-growing non-Hodgkin's lymphoma.

Key Points: 
  • City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States, and Institute for Follicular Lymphoma Innovation (IFLI) today announced a $2 million, three-year collaboration to study spontaneous remission in follicular lymphoma, the most common, slow-growing non-Hodgkin's lymphoma.
  • The collaboration aims to understand the tumor microenvironment in patients whose follicular lymphoma goes into remission without any treatment while being monitored over time.
  • City of Hope will analyze patient samples of follicular lymphoma and spontaneous remission of follicular lymphoma with leading-edge technologies, such as spatial proteomics and transcriptomics, as well as machine learning techniques to help explain why spontaneous remission of follicular lymphoma occurs in a rare number of patients and not in others.
  • The study aims to determine the most relevant prognostic genetic, transcriptomic and microenvironmental factors involved in spontaneous remission of follicular lymphoma.

Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US

Retrieved on: 
Thursday, July 25, 2024
Actinium, Patient, BMT, CD33, Synthase, ARC, FLT3, Radiopharmaceutical, CD45, TP53, Haematopoietic system, Treatment, Pharmaceutical industry

NEW YORK, July 25, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that the Company will participate in the 3rd Annual Targeted Radiopharmaceuticals Summit US, being held in San Diego, CA, from July 30 – August 1, 2024.

Key Points: 
  • NEW YORK, July 25, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that the Company will participate in the 3rd Annual Targeted Radiopharmaceuticals Summit US, being held in San Diego, CA, from July 30 – August 1, 2024.
  • Actinium's presentation titled, "Overcoming Adverse Cytogenetics, TP53, Other Mutations & Treatment Resistant Disease in Relapsed/Refractory AML Using Antibody Radiation Conjugates," will take place on Wednesday, July 31, 2024th.
  • The presentation will highlight the following:
    Exploring Iomab-B, a CD45 I-131 ARC, to enable bone marrow transplant (BMT) in otherwise ineligible patients, while Actimab-A, a CD33 Ac-225 ARC, demonstrates strong anti-leukemic activity
    Outlining responses in heavily pretreated patients for both Iomab-B and Actimab-A, including prior venetoclax treatment or TP53-mutated disease, to demonstrate how targeted radiotherapies offer broad therapeutic potential as backbone regimens
    Revealing preclinical data to further show the benefits of combining Actimab-A with targeted therapies, such as FLT3 inhibitors, to enhance anti-tumor response
    For more information about the Targeted Radiopharmaceutical Summit and the conference agenda, please visit https://targeted-radiopharma-us.com/ .